In addition to our own research and development activities, Crucell has formed strategic agreements with several leading companies. Through these agreements, our technologies are playing a vital role in the development of a number of vaccine and antibody products.
In December 2007, Crucell and sanofi pasteur signed an exclusive collaboration and commercialization agreement for Crucell's rabies monoclonal antibodies, next-generation rabies biologicals, to be used with rabies vaccine for post-exposure prophylaxis against this fatal disease.
In July 2007 Crucell entered into a co-exclusive license agreement with Wyeth Pharmaceuticals, a division of Wyeth, for the use of our PER.C6® and Advac® technology.
In March 2008 both companies entered into an exclusive vaccine development agreement. Crucell is responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities takes place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland.